Insider Buying: Hemogenyx Pharmaceuticals PLC (HEMO) Insider Acquires 200,000 Shares of Stock

Hemogenyx Pharmaceuticals PLC (LON:HEMO) insider Adrian Beeston acquired 200,000 shares of Hemogenyx Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The stock was acquired at an average price of GBX 2 ($0.03) per share, with a total value of £4,000 ($5,608.52).

Hemogenyx Pharmaceuticals PLC (HEMO) opened at GBX 2.20 ($0.03) on Monday. Hemogenyx Pharmaceuticals PLC has a one year low of GBX 2 ($0.03) and a one year high of GBX 3.94 ($0.06). The firm has a market cap of $7.02 and a P/E ratio of -219.99.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/insider-buying-hemogenyx-pharmaceuticals-plc-hemo-insider-acquires-200000-shares-of-stock.html.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, formerly Silver Falcon Plc, is a biotechnology company. The Company is focused on developing new treatments for blood diseases such as leukaemia, lymphoma and blood marrow failure. Its therapies are designed to provide new treatments in bone marrow/stem cell transplants, improving the success and safety of such treatments.

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply